2024年5月29日 · WTX-124 is a half-life extended, masked cytokine (INDUKINE molecule) rationally engineered to release wild type IL-2 in tumors. We previously reported that WTX-124 …

2022年5月3日 · Here, we describe the design and characterization of a conditionally activated IL-2 prodrug, WTX-124, that takes advantage of the dysregulated protease milieu of tumors.

2023年11月3日 · Preliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid …

• Our work shows that WTX-124, a pro-drug containing wild-type IL-2, is selectively processed and activated in tumors and is efficacious in murine models, even in the presence of regulatory …

2022年5月3日 · WTX-124, an IL-2 containing INDUKINE protein, was designed to enhance the clinical profile of rhIL-2 treatment by facilitating less frequent systemic delivery, increasing the …

2022年6月15日 · To address these limitations, we designed WTX-124, an IL-2 pro-drug (IL-2 INDUKINE™ protein) that takes advantage of dysregulated protease activity in the tumor …

Distinct from other next-generation IL-2 molecules, WTX-124 is designed to release a fully potent, wild-type cytokine in tumors. In preclinical models, the released IL-2 causes expansion and …

718 WTX-124 is a novel IL-2 pro-drug that is conditionally activated in tumors and drives antitumor immunity in murine syngeneic cancer models. Background Cancer immunotherapy …

2021年7月1日 · This work presents data summarizing the discovery, biochemical, cellular, and in vivo activity of our lead IL-2 INDUKINE TM WTX-124 and reviews the mechanism of action of …

2023年10月31日 · Interim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 including safety and preliminary antitumor …